Dole Affiliate Receives Social Responsibility in Action Award in Costa Rica
The American-Costa Rican Chamber of Commerce (AmCham) recognized Dole through its daughter company, Standard Fruit Company de Costa Rica S.A., with the Social Responsibility in Action Award in the Employees Category for their project "De la Mano con Dole" — which loosely translates to "Hand-in-Hand with Dole". This year marks the 25th anniversary of the award which was given December 8, 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220119005875/en/
From left: Sandra Lima, Dole Corporate Social Responsibility Senior Manager; Steve Aronson, Horizonte Positivo Board Member; Ana Cristina Obregón, Dole Logistics & Planning Senior Director; Renato Acuña, President of Dole Fresh Fruit Latin America; Gisela Sánchez, AmCham Board President; and Marco Tulio Escobedo, Dole Human Resources Director (Photo: Business Wire)
The Hand-in-Hand with Dole project is an initiative that works towards positively impacting the social development of Standard Fruit Company of Costa Rica (aka Dole Costa Rica) employees and their families, using the Business Multidimensional Business Index (bMPI) methodology developed by the University of Oxford.
The bMPI methodology seeks to measure poverty—not only from the traditional way of per capita income—but also by incorporating dimensions such as, access to health, education, housing, work, social protection and 16 other key indicators. This allows the organization to identify gaps in social programs and work towards solving the multidimensional poverty issues confronted by their employees and their relatives.
Dole is the first agribusiness company in the world to apply the bMPI methodology to address the challenges of social development.
During the diagnostic stage of implementation, Dole Costa Rica achieved a participation rate of 87% in response to socioeconomic surveys among its more than 5300 employees, ranking near the highest level of participation among the companies that have applied the method in the country.
Analysis of the discovered “deficiencies” refocused short-term priorities of the company towards the prevention of disease and the health of our employees at the onset of Covid, to longer term strategies of social protection and health. At the end of September 2021, 500 gaps had been closed.
“We are very proud of being the first banana and pineapple producer to implement this system and seeing such positive results for our employees and families here in Costa Rica,” said Mr. Renato Acuña, President of Dole Fresh Fruit Latin America. “The strategies developed in this program, including social counseling and community care projects, seek to meet needs and provide the necessary capacities for better human development.”
For this project, Dole management has prioritized addressing the following needs: people without health insurance; people with disabilities not receiving state assistance; older adults without a pension, people out of the workforce due to family obligations; and households without drinking water.
In applying findings, Dole has established strategic alliances with Horizonte Positivo, a local NGO that leads the implementation of bMPI in Costa Rica, and with Sophia Oxford, an international non-profit organization that seeks to impact the social investment of companies and the lives of their employees. These third-party interpretations and analyses of results, and the proposal of solutions that can positively affect the reduction of multidimensional poverty, are essential to best practices in solution implementation.
In 2020, Dole introduced its three-pillared Sustainability Framework, The Dole Way, and its ongoing commitment For Food, For Nature and For People. Just as Dole Costa Rica was a pioneer more than 20 years ago in the development of global environmental management systems in agriculture to frame its efforts 'For Nature'; at the beginning of this decade the company intends through this project, to innovate in the establishment of a social development platform focused on its most important resource: 'For People'."
About Dole
Dole plc is one of the world’s largest producers and marketers of high-quality fresh fruit and fresh vegetables. Dole is an industry leader in many of the products it sells, as well as in nutrition education and research. For more information, please visit www.dole.com or www.doleplc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220119005875/en/
Contact information
US Contact: William Goldfield
818-874-4647
william.goldfield@dole.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
